An <i>MGRN1</i>-Based Biomarker Combination Accurately Predicts Melanoma Patient Survival.

ABSTRACT: With ever-increasing incidence and high metastatic potential, cutaneous melanoma is the deadliest skin cancer. Risk prediction based on the Tumor-Node-Metastasis (TNM) staging system has medium accuracy with intermediate IIB-IIIB stages, as roughly 25% of patients with low-medium-grade TNM, and hence a favorable prognostic, undergo an aggressive disease with short survival and around 15% of deaths arise from metastases of thin, low-risk lesions. Therefore, reliable prognostic biomarkers are required. We used genomic and clinical information of melanoma patients from the TCGA-SKCM cohort and two GEO studies for discovery and validation of potential biomarkers, respectively. Neither mutation nor overexpression of major melanoma driver genes provided significant prognostic information. Conver

SUBMITTER: Sanchez-Beltran J 

PROVIDER: S-EPMC11855888 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature